Cost-Effectiveness Analysis of Interferon Beta-1b for the Treatment of Patients With a First Clinical Event Suggestive of Multiple Sclerosis

Clinical Therapeutics

Volumn 34, Issue 5, 2012, Pages 1132-1144

  Caloyeras, John P ^a,b   Zhang, Bin ^a   Wang, Cheng ^c   Eriksson, Marianne ^d   Fredrikson, Sten ^e   Beckmann, Karola ^f   Knappertz, Volker ^c   Pohl, Christoph ^f,g   Hartung, Hans Peter ^h   Shah, Dhvani ⁱ   Miller, Jeffrey D ^a   Sandbrink, Rupert ^f,h   Lanius, Vivian ^f   Gondek, Kathleen ^c   Russell, Mason W ^a  

^a Formerly Abt Bio Pharma Solutions Inc   (United States)

^b RAND CORPORATION   (United States)

^c Bayer HealthCare Pharmaceuticals Inc   (United States)

^d Bayer AB   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f BAYER PHARMA AG   (Germany)

^g UNIVERSITY HOSPITAL BONN   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

BENEFIT trial; Cost effectiveness; Interferon 1b; Multiple sclerosis; Sweden

Indexed keywords

INTERFERON BETA SERINE;

ARTICLE; CLINICALLY DEFINITE MULTIPLE SCLEROSIS; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; QUALITY OF LIFE; RELAPSE; SENSITIVITY ANALYSIS; SWEDEN; THERAPY DELAY;

ADJUVANTS, IMMUNOLOGIC; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE COSTS; HUMANS; INTERFERON-BETA; MARKOV CHAINS; MODELS, ECONOMIC; MULTIPLE SCLEROSIS; QUALITY-ADJUSTED LIFE YEARS; SWEDEN; TIME FACTORS;

EID: 84860765556     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.03.004     Document Type: Article

References (28)

1. Sundström P., Nyström L., Forsgren L. Incidence (1988-97) and prevalence (1997) of multiple sclerosis in Vasterbotten County in northern Sweden. J Neurol Neurosurg Psychiatry 2003, 74:29-32.
2. Berg J., Lindgren P., Fredrikson S., Kobelt G. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 2006, 7:S75-S85.
3. Miller D., Barkhof F., Montalban X., et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005, 4:281-288.
4. Miller D., Barkhof F., Montalban X., et al. Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non conventional MRI, recovery processes, and management. Lancet Neurol 2005, 4:341-348.
5. Murphy N., Confavreux C., Haas J., et al. Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 1998, 13:607-622.
6. Interferon beta 1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double blind, placebo controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993, 43:655-661. [No authors listed].
7. Interferon beta 1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995, 45:1277-1285. [No authors listed].
8. Kappos L., Polman C.H., Freedman M.S., et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242-1249.
9. Kappos L., Freedman M.S., Polman C.H., et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007, 370:389-397.
10. Kappos L., Freedman M.S., Polman C.H., et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009, 8:987-997.
11. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983, 13:227-231.
12. Bell C., Graham J., Earnshaw S., et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007, 13:245-261.
13. Chilcott J., McCabe C., Tappenden P., et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ 2003, 326:522.
14. Gani R., Giovannoni G., Bates D., et al. Cost-effectiveness analyses of natalizumab (tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 2008, 26:617-627.
15. Iskedjian M., Walker J.H., Gray T., et al. Economic evaluation of avonex (interferon beta-Ia) in patients following a single demyelinating event. Mult Scler 2005, 11:542-551.
16. Kobelt G., Berg J., Lindgren P., et al. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult Scler 2008, 14:679-690.
17. Lazzaro C., Bianchi C., Peracino L., et al. Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b. J Neurol Sci 2009, 30:21-31.
18. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
19. Prosser L.A., Kuntz K.M., Bar-Or A., Weinstein M.C. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 2004, 7:554-568.
20. Runmarker B., Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993, 116:117-134.
21. Weinshenker B.G., Bass B., Rice G.P., et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989, 112:133-146.
22. Goodkin D.E., Hertsgaard D., Rudick R.A. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol 1989, 46:1107-1112.
23. Weinshenker B.G., Ebers G.C. The natural history of multiple sclerosis. Can J Neurol Sci 1987, 14:255-261.
24. Weinshenker B.G., Bass B., Rice G.P., et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989, 112:1419-1428.
25. Population Statistics. Statistics Sweden Accessed January 30, 2010. http://www.scb.se/Pages/ProductTables____25809.aspx.
26. General guidelines for economic evaluactions from the Pharmaceutical Benefirts Board (LFNAR2003:2) April 24, 2003, The Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket).
27. The Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket), Accessed August 12, 2009. http://www.tlv.se.
28. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-1108.